Compare Jumia Technologies AG - ADR (JMIA) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jumia Technologies AG - ADR vs Travere Therapeutics Inc. Common Stock — how do they compare? Jumia Technologies AG - ADR trades at $5.74 (market cap $789.73M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 6.2× Jumia Technologies AG - ADR's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Jumia Technologies AG - ADR for 29 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| JMIA | TVTX | |
|---|---|---|
Market Cap | $789.73M | $4.88B |
Volume | 1,367,204 | 1,668,577 |
Sector | Consumer Cyclical | Health |
52-Week High | $14.60 | $67.52 |
52-Week Low | $5.69 | $26.79 |
Typical Hold Time | 29 Days | 0 Days |
Enterprise Value | $755.37M | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JMIA stock trades at $5.79, down 5.24% on the day, amid a bearish technical outlook with all moving averages signaling sell. Fundamentally, the company reported a net loss of $61.55 million in 2025, though revenue grew to $188.93 million and the net loss margin improved to -32.58%. Recent news highlights a $50 million capital raise and progress toward EBITDA breakeven by year-end 2026, per company reports from August 2026.
The outlook is mixed: analyst consensus is bullish with a $12 price target, but high execution risks persist given persistent losses and negative ROE. Investors face volatility from operational cash burn and competitive pressures in African e-commerce, though cost controls and growth initiatives offer potential upside if profitability targets are met.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
